Armata Pharmaceuticals Files 8-K

Ticker: ARMP · Form: 8-K · Filed: May 19, 2025 · CIK: 921114

Armata Pharmaceuticals, INC. 8-K Filing Summary
FieldDetail
CompanyArmata Pharmaceuticals, INC. (ARMP)
Form Type8-K
Filed DateMay 19, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 8-K, disclosure, financials

TL;DR

Armata Pharma dropped an 8-K, could be big news.

AI Summary

Armata Pharmaceuticals, Inc. filed an 8-K on May 19, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or details about the nature of the disclosure.

Why It Matters

This 8-K filing indicates that Armata Pharmaceuticals has made a significant disclosure to the SEC, which could impact investors' understanding of the company's current status.

Risk Assessment

Risk Level: medium — The filing is an 8-K, which often contains material information, but the provided text lacks specific details to assess the immediate impact.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by Armata Pharmaceuticals?

The filing is for a Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically for Regulation FD Disclosure and Financial Statements and Exhibits.

On what date was the earliest event reported in this filing?

The date of the earliest event reported is May 19, 2025.

What is Armata Pharmaceuticals' principal executive office address?

The principal executive offices are located at 5005 McConnell Avenue, Los Angeles, California, 90066.

What is Armata Pharmaceuticals' state of incorporation?

Armata Pharmaceuticals, Inc. is incorporated in Washington.

What is the IRS Employer Identification Number for Armata Pharmaceuticals?

The IRS Employer Identification Number for Armata Pharmaceuticals is 91-1549568.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 19, 2025 regarding Armata Pharmaceuticals, Inc. (ARMP).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing